Unlock stock picks and a broker-level newsfeed that powers Wall Street.

CEN Biotech Inc., a Wholly-Owned Subsidiary of Creative Edge Nutrition, Inc. Completes Spin Off Announces Bill Chaaban, President and CEO

BEVERLY HILLS, CA and LAKESHORE, ON / ACCESSWIRE / September 24, 2015 / Creative Edge Nutrition, Inc. (FITX), a nutritional supplement company focusing on active lifestyles, announces an update to its shareholders.

http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001653821&owner=exclude&count=40&hidefilings=0

On September 23, 2015, the Board of Directors of Creative Edge Nutrition, Inc. ("FITX") approved the spinoff of its wholly-owned subsidiary, CEN Biotech, Inc. ("CEN"), to the shareholders of FITX. CEN is involved in the prospective medical marijuana business and is attempting to obtain the necessary license and approval under the Marijuana for Medical Purposes Regulations in Canada. CEN has completed the construction of its production facility, and is prepared to immediately begin production of medical marijuana once all licenses and approvals are obtained.

Shareholders of FITX, as of the close of business on November 30, 2015 will receive 1 share of CEN Biotech, Inc. common stock for every 700 common shares of FITX owned on the record date of November 30, 2015. The total shares of CEN will be 7,000,000 which is comprised of 6,900,000 common shares and 100,000 preferred shares. CEN is currently planning to have its shares traded on the OTC Markets QB. FITX will continue to trade on the OTC Markets Pink.

CEN engaged Thayer O' Neal, CPAs to perform the company audit. This audit is now complete and the audited financial statements are included in a Form 10 filed with the Securities and Exchange Commission on September 23, 2015. Thayer O' Neal is a full service public accounting firm which provides professional accounting, auditing and tax services to a number of publicly and privately held companies.

The Company will issue a comprehensive press release shortly outlining the status of its pending litigation and other efforts seeking to overturn Health Canada's arbitrary denial of its license to produce medicinal marijuana. The Company is also continuing its endeavors to procure a detailed and meaningful zoning designation of its Lakeshore, Canada properties, consistent with the town council's initial holding that CEN Biotech's properties had "the correct zoning". The fact of proper zoning is memorialized in the minutes of Lakeshore's town Council meeting of November 7, 2013. The Company remains strongly committed to its pursuit of justice in procuring its license to produce. The spinoff is a testament of CEN Biotech's confidence in its ability to execute to its original strategy and obtain all licensing and approvals necessary. Despite the continued and unjustified bashing from press and stock short sellers, CEN Biotech remains fully committed to its shareholders and its business plan.